Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2023 · 91 positions · Total reported value $1.08B · Top-10 concentration 42.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2023 13F filing, Soleus Capital Management, L.P. disclosed 91 equity positions with a combined reported value of $1.08B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 42.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were XBI ($91.28M), UTHR ($64.86M), TEVA ($61.73M). By sector, the heaviest allocations are Health Care 72.7%, Consumer Staples 1.2%.

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions.

The largest new positions opened in Q3 2023 were XBI ($91.28M), UTHR ($64.86M), TEVA ($61.73M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • XBI SPDR SERIES TRUST · $91.28M
  • UTHR UNITED THERAPEUTICS CORP DEL · $64.86M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · $61.73M
  • FOCL EDAP TMS S A · $43.92M
  • SRDX SURMODICS INC · $39.50M
  • ORGO ORGANOGENESIS HLDGS INC · $39.10M
  • GSK GSK PLC · $34.18M
  • HUM HUMANA INC · $33.47M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 72.7%
Materials 0.7%
Other 25.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.25M $91.28M 8.42%
8.42%
New
2 287.17K $64.86M 5.98%
5.98%
New
3 6.05M $61.73M 5.70%
5.70%
New
4 6.26M $43.92M 4.05%
4.05%
New
5 1.23M $39.50M 3.64%
3.64%
New
6 12.30M $39.10M 3.61%
3.61%
New
7 943.00K $34.18M 3.15%
3.15%
New
8 68.80K $33.47M 3.09%
3.09%
New
9 628.21K $27.87M 2.57%
2.57%
New
10 499.65K $25.47M 2.35%
2.35%
New
11 1.91M $25.01M 2.31%
2.31%
New
12 2.88M $24.11M 2.23%
2.23%
New
13 2.47M $24.00M 2.21%
2.21%
New
14 643.78K $23.10M 2.13%
2.13%
New
15 1.93M $21.72M 2.00%
2.00%
New
16 127.68K $20.36M 1.88%
1.88%
New
17 2.08M $18.99M 1.75%
1.75%
New
18 3.79M $18.93M 1.75%
1.75%
New
19 96.06K $18.83M 1.74%
1.74%
New
20 2.06M $18.80M 1.73%
1.73%
New
21 2.81M $16.90M 1.56%
1.56%
New
22 237.50K $16.60M 1.53%
1.53%
New
23 653.90K $16.20M 1.49%
1.49%
New
24 14.80M $15.99M 1.48%
1.48%
New
25 399.60K $15.34M 1.42%
1.42%
New
26 117.89K $13.68M 1.26%
1.26%
New
27 642.29K $13.64M 1.26%
1.26%
New
28 192.55K $13.44M 1.24%
1.24%
New
29 306.00K $13.40M 1.24%
1.24%
New
30 4.29M $13.25M 1.22%
1.22%
New
31 9.68M $12.48M 1.15%
1.15%
New
32 1.41M $11.58M 1.07%
1.07%
New
33 1.35M $10.95M 1.01%
1.01%
New
34 98.00K $10.65M 0.98%
0.98%
New
35 549.18K $10.08M 0.93%
0.93%
New
36 451.16K $10.02M 0.92%
0.92%
New
37 325.00K $9.59M 0.89%
0.89%
New
38 384.49K $9.07M 0.84%
0.84%
New
39 391.80K $7.87M 0.73%
0.73%
New
40 4.36M $7.41M 0.68%
0.68%
New
41 343.98K $7.18M 0.66%
0.66%
New
42 964.55K $7.14M 0.66%
0.66%
New
43 154.42K $7.10M 0.66%
0.66%
New
44 35.60K $7.06M 0.65%
0.65%
New
45 102.20K $6.97M 0.64%
0.64%
New
46 814.00K $6.40M 0.59%
0.59%
New
47 439.00K $6.06M 0.56%
0.56%
New
48 8.30M $5.81M 0.54%
0.54%
New
49 1.24M $5.64M 0.52%
0.52%
New
50 344.10K $5.56M 0.51%
0.51%
New

FAQ

What did Soleus Capital Management, L.P. buy in 2023-Q3?

In its 2023-Q3 13F filing, Soleus Capital Management, L.P. reported 91 equity positions worth $1.08B in aggregate; its largest disclosed positions were XBI ($91.28M), UTHR ($64.86M), TEVA ($61.73M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.08B of long equity holdings across 91 positions as of 2023-Q3. Top-10 holdings account for 42.6% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →